But those results are likely irrelevant
Sobo or their prescribing clinician when side effects are persistent, worsening, confusing, or interfering with nutrition, hydration, bowel function, energy, sleep, or daily life
Individuals without severe gastrointestinal disease , active pancreatitis, or other contraindications relevant to incretin-based therapies
[11] [12] Currently available GLP-1 receptor agonists in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GLP-1/GIP receptor agonist
Lead researcher Dr
Assists in reduction of body fat and visceral adiposity